8-K: Pure Bioscience Secures $500,000 in Convertible Debt Financing with Potential for $3 Million Total

Pure Bioscience, Inc. has entered into a Note Purchase Agreement, securing an initial $500,000 in convertible promissory notes with the possibility of raising up to $3 million.

Summary

• Pure Bioscience, Inc. has entered into a Note Purchase Agreement to issue convertible promissory notes.
• The initial closing provides $500,000 in funding, with potential for subsequent closings up to a total of $3 million.
• The notes accrue interest at 7.88% per year, compounded annually.
• The principal and accrued interest are due three years from the issuance date, or earlier upon demand by the lender.
• The notes are convertible into common stock at a price based on the 30-day volume-weighted average price (VWAP) of the company's stock, with a minimum of $0.095 and a maximum of $0.175 per share.
• A majority of noteholders can elect to convert all notes after one year at the VWAP, with a minimum price of $0.095 per share.
• In the event of a corporate transaction, all outstanding principal and interest will automatically convert into shares based on the VWAP prior to the announcement of the transaction.
• The notes are unsecured obligations of the company.

Sentiment

Score: 6

Explanation: The document indicates a positive development for the company in securing funding, but the terms of the debt and potential dilution temper the overall sentiment. The potential for further funding is a positive, but the risks associated with convertible debt are also present.

Positives

• The company has secured immediate funding of $500,000.
• There is a potential for further funding up to $3 million, providing additional financial flexibility.
• The conversion feature allows for potential equity upside for lenders.
• The interest rate of 7.88% is a reasonable cost of capital for the company.
• The agreement includes standard protections for lenders, such as events of default and covenants.

Negatives

• The notes are unsecured, meaning lenders have no specific assets to claim in case of default.
• The company is obligated to pay interest and principal, which could strain cash flow.
• The conversion of notes could dilute existing shareholders.
• The company is subject to certain covenants, which could restrict its operational flexibility.
• The notes can be converted at the option of the lenders, which could lead to unexpected dilution.

Risks

• The company may not be able to raise the full $3 million in subsequent closings.
• The conversion price of the notes is subject to market fluctuations, which could impact the number of shares issued.
• The company may not be able to meet its obligations under the notes, leading to default.
• The company's stock price could fall below the minimum conversion price, potentially impacting the value of the notes.
• The company's ability to operate is subject to compliance with various covenants.

Future Outlook

The company intends to use the funds for general corporate purposes and may conduct subsequent closings to reach the $3 million target. The conversion of the notes into equity could impact the company's capital structure in the future.

Management Comments

• The disinterested members of the Board approved the Private Placement.
• Robert Bartlett, Chief Executive Officer & President, signed the agreement on behalf of Pure Bioscience, Inc.

Industry Context

This type of financing is common for small-cap companies seeking to raise capital. Convertible debt allows companies to access funding while providing investors with the potential for equity upside. The terms of the agreement, such as the interest rate and conversion price, are typical for this type of transaction.

Comparison to Industry Standards

• The 7.88% interest rate is within the typical range for convertible debt issued by small-cap companies.
• The conversion price range of $0.095 to $0.175 per share is common for companies with volatile stock prices.
• The three-year maturity is a standard term for convertible notes.
• The inclusion of a VWAP-based conversion price is a common mechanism to protect investors from short-term price fluctuations.
• Similar companies such as Xometry and Nano Dimension have used convertible debt to raise capital, often with similar terms and conditions.

Related Party Transactions

• Mr. Tom Y. Lee, a member of the Company's Board of Directors, invested $500,000 in the Private Placement.

Stakeholder Impact

• Shareholders may experience dilution if the notes are converted into equity.
• Lenders have the potential for equity upside through the conversion feature.
• The company's employees may benefit from the additional funding, which could support operations and growth.
• The company's creditors may be impacted by the new debt obligations.

Next Steps

• The company will likely proceed with subsequent closings to raise the remaining $2.5 million.
• The company will need to manage its debt obligations and ensure compliance with the covenants.
• The company will need to monitor its stock price to manage the potential conversion of the notes into equity.

Key Dates

Keywords

convertible promissory notes, private placement, debt financing, common stock, conversion, interest rate, note purchase agreement, funding, VWAP, dilution